一名IV期肺腺癌患者伴有罕见/复合表皮生长因子受体（EGFR）突变且对阿法替尼有反应的病例报告。
Case report of a patient with stage IV lung adenocarcinoma and uncommon/compound EGFR mutations who responded to afatinib.
作者信息
Hirokawa Hisanori, Hirata Hirokuni, Azuma Hayase, Sugitate Kei, Soda Sayo, Matsushima Jun, Fukushima Yasutsugu
机构信息
Department of Respiratory Medicine and Clinical Immunology, Dokkyo Medical University, Saitama Medical Center, 2-1-50 Minamikoshigaya, Koshigaya, Saitama, 343-0845, Japan.
Department of Respiratory Medicine and Clinical Immunology, Dokkyo Medical University, 880 Kitakobayashi, Shimotusga-gun, Tochigi, 321-0293, Japan.
出版信息
Respir Med Case Rep. 2024 Aug 22;51:102094. doi: 10.1016/j.rmcr.2024.102094. eCollection 2024.
There is no established treatment for lung adenocarcinoma with uncommon/compound epidermal growth factor receptor (EGFR) mutations. We report a case of a 73-year-old man with stage IVB lung adenocarcinoma harboring E709G and L861Q EGFR mutations. After 2 months of afatinib treatment, significant tumor shrinkage was observed, and the patient's condition remained stable for 1 year. This case highlights the potential effectiveness of afatinib for treating rare stage IV lung adenocarcinoma with these specific EGFR mutations.
对于具有罕见/复合表皮生长因子受体（EGFR）突变的肺腺癌，目前尚无既定的治疗方法。我们报告了一例73岁男性IVB期肺腺癌患者，其携带E709G和L861Q EGFR突变。接受阿法替尼治疗2个月后，观察到肿瘤显著缩小，患者病情稳定了1年。该病例突出了阿法替尼治疗具有这些特定EGFR突变的罕见IV期肺腺癌的潜在有效性。
Zotero 插件